Evidence map›Paper›PMID 32924986›Full record

ArticleCancer biomarkers : section A of Disease markers2021

MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study.

Łukasz Białek, Katarzyna Czerwińska, Łukasz Fus, Wojciech Krajewski, Anna Sadowska, Piotr Radziszewski, Jakub Dobruch, Piotr Kryst, Sławomir Poletajew

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03796299 (Expression of MCM5 in Urine in Patients With Urothelial Cancers), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03796299 unknown statusnot on this map

Expression of MCM5 in Urine in Patients With Urothelial Cancers

TypeobservationalSponsorMedical University of WarsawRan2019 to 2019Enrolled180ConditionsBladder CancerArmsAssessment of expression of MCM5 in the urine (ADX Bladder)
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?International journal of environmental research and public health · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Łukasz BiałekFirst Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Katarzyna CzerwińskaDepartment of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Łukasz FusDepartment of Pathology, Medical University of Warsaw, Warsaw, Poland.
Wojciech KrajewskiDepartment and Clinic of Urology, Medical University of Wroclaw, Wroclaw, Poland.
Anna SadowskaDepartment of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Piotr RadziszewskiDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Jakub DobruchFirst Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Piotr KrystSecond Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Sławomir PoletajewSecond Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Medical University of Warsaw · PLPostgraduate School of Molecular Medicine · PLUniversity of Wrocław · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMini Chromosome Maintenance 5 (MCM5) is considered as a urinary biomarker of bladder cancer. ADXBLADDER is a commercially available test to detect MCM5 antibodies.

objectiveExternal validation of ADXBLADDER test as a urinary biomarker of histopathologically confirmed non-muscle invasive bladder cancer (NMIBC) recurrence.

methodsThe study enrolled 119 consecutive patients with a history of NMIBC and 37 healthy volunteers matched as controls. Single, full-void urine samples were collected from patients before cystoscopy ± TUR. To measure MCM5 expression, Arquer Diagnostics ADXBLADDER test was used. The study protocol was registered within the clinical trials database (NCT03796299).

resultsAmong patients with NMIBC history, recurrence was diagnosed in 83 patients (69.7%). ADXBLADDER demonstrated sensitivity of 73.5% (95% confidence interval (CI) 62.7%-82.6%), specificity of 33.3% (95% CI 18.6% to 51%), overall negative predictive value (NPV) of 35.3% (95% CI 23.3% to 49.5%) and overall positive predictive value of 71.8% (95% CI 66.1% to 76.8%) for detecting recurrence. In a control group, false positive ADXBLADDER results were noticed in 18 patients (48.6%). The sensitivity and NPV were the highest in invasive tumors (100% and 100%, respectively) and in high-grade recurrences (81.8% and 94.1%, respectively).

conclusionsADXBLADDER has a moderate sensitivity and poor specificity in detecting NMIBC recurrence. However, it properly diagnoses patients with T1+ stage recurrence or high-grade tumors.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesCell Cycle ProteinsFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesUrinary Bladder NeoplasmsBiomarkers, TumorCell Cycle ProteinsMCM5 protein, humanADXBLADDERbiomarkerMCM5Urothelial cancer

Identifiers

PMID32924986
PMCPMC12499985
OpenAlexW3085601548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.